Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 875 results found since Jan 2013.

Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats
AbstractStatins are widely used in high-risk patients to reduce the stroke incidence. However, little has been investigated about the impact of chronic pretreatment with statins on cerebral ischemic insult following defined arterial occlusion. To address this in experimental rats, in the present work, atorvastatin was orally dosed for 1  month to evaluate the outcomes of the subsequent occlusive stroke induced by middle cerebral artery occlusion (MCAO). Our data was suggestive of potential escalating impact of chronic atorvastatin (Atv; 10 mg/kg) on neurological function, but not infarct volume. According to our immunobl...
Source: Journal of Molecular Neuroscience - August 18, 2016 Category: Neuroscience Source Type: research

Atorvastatin Attenuates Ischemia/Reperfusion-Induced Hippocampal Neurons Injury Via Akt-nNOS-JNK Signaling Pathway.
In this study, four-vessel occlusion model was established in rats with cerebral ischemia. Rats were divided into five groups: sham group, I/R group, I/R+ATV group, I/R+ATV+LY, and I/R+SP600125 group. Cresyl violet staining was carried out to examine the neuronal death of hippocampal CA1 region. Immunoblotting was used to detect the expression of the related proteins. Results showed that ATV significantly protected hippocampal CA1 pyramidal neurons against cerebral I/R. ATV could increase the phosphorylation of protein kinase B (Akt1) and nNOS, diminished the phosphorylation of JNK3 and c-Jun, and further inhibited the act...
Source: Cellular and Molecular Neurobiology - August 2, 2016 Category: Cytology Authors: Shao S, Xu M, Zhou J, Ge X, Chen G, Guo L, Luo L, Li K, Zhu Z, Zhang F Tags: Cell Mol Neurobiol Source Type: research

Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients
Background/Aims: The aim of the present study is to investigate whether the single nucleotide polymorphism (SNP) in lipid metabolism related genes would affect the effectiveness of atorvastatin in both Han and Uighur populations. Methods: 200 ischemic stroke patients were treated with atorvastatin. The differences of blood lipid level and their ratios were measured. Six lipid related genes, HMGCR, APOA5, LPL, CETP, LDLR and PCSK9 were selected as candidate genes. And nine SNP loci in these six genes were genotyped by SNaPshot technique. Results: In all patients treated with atorvastatin, the SNP rs662799 significantly affe...
Source: Cellular Physiology and Biochemistry - July 14, 2016 Category: Cytology Source Type: research

Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
CONCLUSIONS: High potency lipid-lowering therapy effectively reduces the risk of recurrent IS in diabetic patients regardless of ATOR or EZ-SIM combination therapy. PMID: 27270238 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 5, 2016 Category: Endocrinology Authors: Liu CH, Chen TH, Lin MS, Hung MJ, Chung CM, Cherng WJ, Lee TH, Lin YS Tags: J Clin Endocrinol Metab Source Type: research

In this Issue
The 4D Study was a randomized trial comparing 4 years of treatment with atorvastatin to placebo in 1255 hemodialysis patients with type 2 diabetes. In the original trial, atorvastatin did not significantly reduce the primary end point of cardiovascular events, including cardiac death, myocardial infarction, and stroke. To determine the long-term effects of atorvastatin in these patients, Krane and co-workers used questionnaires to assess clinical outcomes in surviving 4D participants. After median follow-up of 11.5 years, participants who had been assigned to atorvastatin had a nonsignificant trend toward fewer cardiovascu...
Source: Kidney International - May 13, 2016 Category: Urology & Nephrology Tags: In this Issue Source Type: research

Statins and poststroke intracerebral hemorrhage: Concern but increasing reassurance
Post hoc analyses of data from randomized controlled trials can generate useful hypotheses, but need to be considered exploratory. When conducted, such evaluations should adhere to specified criteria and test for a treatment by subgroup interaction for the trial's primary endpoint.1 The best way to proceed if unexpected but potentially important outcomes occur is less clear. Concern that treatment with HMG-CoA reductase inhibitors (i.e., statins) might increase the risk of poststroke intracerebral hemorrhage (ICH) arose from an unanticipated observation in the Stroke Prevention with Aggressive Reduction in Cholesterol Leve...
Source: Neurology - April 24, 2016 Category: Neurology Authors: Goldstein, L. B., Nederkoorn, P. J. Tags: All Cerebrovascular disease/Stroke, Intracerebral hemorrhage EDITORIALS Source Type: research

Comparative Effectiveness of Generic Atorvastatin and Lipitor(R) in Patients Hospitalized with an Acute Coronary Syndrome Health Services and Outcomes Research
Conclusions Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness.
Source: JAHA:Journal of the American Heart Association - April 18, 2016 Category: Cardiology Authors: Jackevicius, C. A., Tu, J. V., Krumholz, H. M., Austin, P. C., Ross, J. S., Stukel, T. A., Koh, M., Chong, A., Ko, D. T. Tags: Atrial Fibrillation, Quality and Outcomes Health Services and Outcomes Research Source Type: research

New drug 'effective' for those with intolerable statin side effects
Conclusion The main results of this study relate to the lipid-lowering effects of two alternative non-statin medications. However, it highlights the muscle-related adverse effects that can occur with statins. The study is carefully designed and has many strengths, including: a washout period between drugs to remove any residual effects double-blind design throughout so people didn't know what they were taking sufficient duration for each phase of the study (10 and 24 weeks) to allow effects to develop a good sample size – the researchers calculated beforehand how many people would need to be recruited to ena...
Source: NHS News Feed - April 4, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news

Atorvastatin Treatment Is Associated with Increased BDNF Level and Improved Functional Recovery after Atherothrombotic Stroke (S31.007)
Conclusions: Our results demonstrated that atorvastatin treatment was associated with increased BDNF level and improved functional recovery after atherothrombotic stroke. This study indicates that atorvastatin-related elevation in BDNF may promote functional recovery in stroke patients.Disclosure: Dr. Zhang has nothing to disclose. Dr. Mu has nothing to disclose. Dr. Gao has nothing to disclose. Dr. Huang has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Zhang, J., Mu, X., Gao, Z., Huang, Y. Tags: Stroke Risk, Outcomes, and Complications Source Type: research

Statin therapy in acute ischemic stroke: Time for large randomized trials?
Despite improvements in stroke mortality coupled with therapeutic advances, stroke patients often face the prospect of substantial disability. Novel strategies are clearly needed to further improve stroke outcomes. These might include new indications for previously licensed drugs proven effective and safe in related disease processes,1 such as statins. Unlike strong evidence supporting statin use in cardiovascular risk reduction and acute myocardial ischemia, their effects on cerebral tissue and potential benefits on stroke outcomes remain poorly understood and understudied. The only current stroke-specific indication for ...
Source: Neurology - March 21, 2016 Category: Neurology Authors: Charidimou, A., Merwick, A. Tags: All Cerebrovascular disease/Stroke, Infarction EDITORIALS Source Type: research

Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial
Abstract: Statins have beneficial effects on cerebral circulation and brain parenchyma during ischemic stroke and reperfusion. The primary hypothesis of this randomized parallel trial was that treatment with 80 mg/day of atorvastatin administered early at admission after acute atherosclerotic ischemic stroke could reduce serum levels of markers of immune-inflammatory activation of the acute phase and that this immune-inflammatory modulation could have a possible effect on prognosis of ischemic stroke evaluated by some outcome indicators. We enrolled 42 patients with acute ischemic stroke classified as large arteries ath...
Source: Medicine - March 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Atorvastatin inhibits miR-143 expression: A protective mechanism against oxidative stress in cardiomyocytes
Statins are unequivocally the most widely prescribed drug for the primary and secondary prevention of coronary artery disease worldwide [1]. Atorvastatin is the most commonly prescribed statin drug due to its lower therapeutic dose comared to others. The well-tolerated and high benefit–risk ration of atorvastain has been demonstrated in clinical trials [2]. Atorvastatin reduce the risk of myocardial infarction, stroke, and death, primarily inhibiting reactive oxygen species (ROS) [3].
Source: International Journal of Cardiology - March 1, 2016 Category: Cardiology Authors: Shanshan Tian, Wei Zhao, Di Yang, Yang Yu, Jiaqi Zou, Zhiyan Liu, Zhimin Du Tags: Correspondence Source Type: research

Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack.
CONCLUSIONS: Compared with atorvastatin 80 mg, atorvastatin 40 mg plus ezetimibe 10 mg increases the likelihood of achieving LDLc goals after ischaemic stroke or transient ischaemic attack. Both treatments were safe and well tolerated. PMID: 26916323 [PubMed - in process]
Source: Revista de Neurologia - February 27, 2016 Category: Neurology Authors: Palacio E, Viadero-Cervera R, Revilla M, Larrosa-Campo D, Acha-Salazar O, Novo-Robledo F, Oterino A Tags: Rev Neurol Source Type: research

Benefit-risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment
Conclusions The results of benefit–risk assessment from every perspective were somewhat consistent. This study demonstrated the feasibility of applying a discrete choice experiment in the benefit–risk assessment of drugs and encouraged the engagement of multiple stakeholders in the decision-making process.
Source: BMJ Open - February 25, 2016 Category: Journals (General) Authors: Wanishayakorn, T., Sornlertlumvanich, K., Ngorsuraches, S. Tags: Open access, Cardiovascular medicine, Health policy Research Source Type: research

Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke
10.3109/00207454.2016.1146882Jingmiao Zhang
Source: International Journal of Neuroscience - February 21, 2016 Category: Neuroscience Authors: Jingmiao ZhangXiali MuDane A BrekerYing LiZongliang GaoYonglu Huang Source Type: research